The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Recent advances in eosinophilia with FGFR rearrangement
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an update on the management of eosinophilia with fibroblast growth factor receptor (FGFR) rearrangement. Encouraging results from the FIGHT-203 study (NCT03011372) evaluating pemigatinib are expected to improve the outcomes of this patient population. This interview took place virtually.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.
